NMS·Healthcare·$909M·#512 / 520 in Healthcare
CTMX CytomX Therapeutics, Inc.
15CRITICAL
CATEGORY BREAKDOWN
GROWTH0
QUALITY0
STABILITY34
VALUATION38
GOVERNANCE3
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
-44.8%
0
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
2 months
3
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
4.3%
97
< 25% strong
Price / Sales
Market cap relative to trailing revenue
11.9x
38
< 3x strong
Rule of 40
Growth rate plus operating margin
-74
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
0.6%
5
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+168.1%
0
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE CTMX WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when CTMX's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.